@article{fb80c8bb10144c2fb78e8a4ba816dad4,
title = "Disability, HRQoL and resource use among chronic and episodic migraineurs: Results from the International Burden of Migraine Study (IBMS)",
abstract = "Background: Migraine imposes significant burden on patients, their families and health care systems. In this study, we compared episodic to chronic migraine sufferers to determine if migraine status predicted headache-related disability, health-related quality of life (HRQoL) and health care resource utilization. Methods: A Web-based survey was administered to panelists from nine countries. Participants were classified as having chronic migraine (CM), episodic migraine (EM) or neither using a validated questionnaire. Data collected and then analyzed included sociodemographics, clinical characteristics, Migraine Disability Assessment, Migraine-Specific Quality of Life v2.1, Patient Health Questionnaire and health care resource utilization. Findings: Of the respondents, 5.7% had CM and 94.3% had EM, with CM patients reporting significantly more severe disability, lower HRQoL, higher levels of anxiety and depression and greater health care resource utilization compared to those with EM. Interpretation: These results provide evidence that will enhance our understanding of the factors driving health care costs and will contribute to development of cost-effective health care strategies.",
keywords = "Chronic migraine, burden, disability, headache, international survey, quality of life, web survey",
author = "Blumenfeld, {A. M.} and Varon, {S. F.} and Wilcox, {T. K.} and Buse, {D. C.} and Kawata, {A. K.} and A. Manack and Goadsby, {P. J.} and Lipton, {R. B.}",
note = "Funding Information: SV and AM are employees of Allergan, Inc. AB has received research grants from Allergan, Pfizer, GlaxoSmithKline (GSK) and Medtronic, has received honoraria from Allergan, Pfizer, GSK, Merck, Ortho-McNeil-Janssen Pharmaceuticals (OMP) and Medtronic, and has consultancy agreements with Allergan, Pfizer and GSK. TW and AK are employees of United BioSource Corporation. DB has received honoraria from Endo, Merck, Iroko, and MAP Pharmaceuticals, and has consultancy agreements with Endo and Allergan. PG has received research grants from MSD, Neuralieve, GSK and Johnson & Johnson and has received honoraria from and has consultancy agreements with Allergan, Almirall, BosSci, Eli Lilly, Endo, MAP, Medtronic, Minster, MSD, Neuralieve, Neuraxon and NeuroTherapeutics Pharma. RL has received research grants from Advanced Bionics, Allergan, GSK, Minster, Merck, Neuralieve, Novartis, OMP, Pfizer and ProEthics/KOWA, has received honoraria from Allergan, AstraZeneca, GSK, Merck, Novartis, OMP and Pfizer, and has consultancy agreements with Advanced Bionics, Allergan, Boehringer Ingelheim, Bristol-Myers Squibb, Cierra, Endo, Neuralieve, Novartis, OMP, Pfizer, Pozen and ProEthics/KOWA. Acknowledgements Funding Information: This study was funded by Allergan, Inc. The study sponsor was involved in the study design, data collection, data analysis, data interpretation and the writing of the article. AB, SV, TW and AK were involved in development of the Web-based questionnaire. The initial first drafts of the introduction and discussion sections of this paper were written by AB and SV. The initial first drafts of the methods and results sections were written by AK and TW. All authors had full access to all of the data. The corresponding author had final responsibility for submission of this paper. Copyright: Copyright 2011 Elsevier B.V., All rights reserved.",
year = "2011",
month = mar,
doi = "10.1177/0333102410381145",
language = "English (US)",
volume = "31",
pages = "301--315",
journal = "Cephalalgia",
issn = "0333-1024",
publisher = "SAGE Publications Ltd",
number = "3",
}